Impact of Spores on the Comparative Efficacies of Five Antibiotics for Treatment of Bacillus anthracis in an In Vitro Hollow Fiber Pharmacodynamic Model

ABSTRACT Bacillus anthracis, the bacterium that causes anthrax, is an agent of bioterrorism. The most effective antimicrobial therapy for B. anthracis infections is unknown. An in vitro pharmacodynamic model of B. anthracis was used to compare the efficacies of simulated clinically prescribed regimens of moxifloxacin, linezolid, and meropenem with the “gold standards,” doxycycline and ciprofloxacin. Treatment outcomes for isogenic spore-forming and non-spore-forming strains of B. anthracis were compared. Against spore-forming B. anthracis, ciprofloxacin, moxifloxacin, linezolid, and meropenem reduced the B. anthracis population by 4 log10 CFU/ml over 10 days. Doxycycline reduced the population of this B. anthracis strain by 5 log10 CFU/ml (analysis of variance [ANOVA] P = 0.01 versus other drugs). Against an isogenic non-spore-forming strain, meropenem killed the vegetative B. anthracis the fastest, followed by moxifloxacin and ciprofloxacin and then doxycycline. Linezolid offered the lowest bacterial kill rate. Heat shock studies using the spore-producing B. anthracis strain showed that with moxifloxacin, ciprofloxacin, and meropenem therapies the total population was mostly spores, while the population was primarily vegetative bacteria with linezolid and doxycycline therapies. Spores have a profound impact on the rate and extent of killing of B. anthracis. Against spore-forming B. anthracis, the five antibiotics killed the total (spore and vegetative) bacterial population at similar rates (within 1 log10 CFU/ml of each other). However, bactericidal antibiotics killed vegetative B. anthracis faster than bacteriostatic drugs. Since only vegetative-phase B. anthracis produces the toxins that may kill the infected host, the rate and mechanism of killing of an antibiotic may determine its overall in vivo efficacy. Further studies are needed to examine this important observation.

[1]  Jerome Hauer,et al.  Anthrax as a biological weapon, 2002: updated recommendations for management. , 2002, JAMA.

[2]  E. Bruck,et al.  National Committee for Clinical Laboratory Standards. , 1980, Pediatrics.

[3]  M. Roberts.  Tetracycline therapy: update. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  J. Todd,et al.  Improved outcome of clindamycin compared with beta-lactam antibiotic treatment for invasive Streptococcus pyogenes infection. , 1999, The Pediatric infectious disease journal.

[5]  B. Ivins,et al.  Determination of Antibiotic Efficacy against Bacillus anthracis in a Mouse Aerosol Challenge Model , 2007, Antimicrobial Agents and Chemotherapy.

[6]  K. Bush,et al.  Effective Antimicrobial Regimens for Use in Humans for Therapy of Bacillus anthracis Infections and Postexposure Prophylaxis , 2005, Antimicrobial Agents and Chemotherapy.

[7]  C. P. Quinn,et al.  Bioterrorism-related inhalational anthrax: the first 10 cases reported in the United States. , 2001, Emerging infectious diseases.

[8]  G. Drusano,et al.  Use of an In Vitro Pharmacodynamic Model To Derive a Linezolid Regimen That Optimizes Bacterial Kill and Prevents Emergence of Resistance in Bacillus anthracis , 2008, Antimicrobial Agents and Chemotherapy.

[9]  N. Bergman,et al.  Transcriptional Profiling of the Bacillus anthracis Life Cycle In Vitro and an Implied Model for Regulation of Spore Formation , 2006, Journal of bacteriology.

[10]  J. Waitz.  Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically , 1990 .

[11]  A. Moir,et al.  Germination of Bacillus cereus spores in response to L-alanine and to inosine: the roles of gerL and gerQ operons. , 2002, Microbiology.

[12]  Update: Investigation of bioterrorism-related anthrax and interim guidelines for exposure management and antimicrobial therapy, October 2001. , 2001, MMWR. Morbidity and mortality weekly report.

[13]  G. Drusano,et al.  Impact of Resistance Selection and Mutant Growth Fitness on the Relative Efficacies of Streptomycin and Levofloxacin for Plague Therapy , 2007, Antimicrobial Agents and Chemotherapy.

[14]  V. Winn,et al.  The Eagle effect revisited: efficacy of clindamycin, erythromycin, and penicillin in the treatment of streptococcal myositis. , 1988, The Journal of infectious diseases.

[15]  G. Drusano,et al.  Differential Effects of Linezolid and Ciprofloxacin on Toxin Production by Bacillus anthracis in an In Vitro Pharmacodynamic System , 2011, Antimicrobial Agents and Chemotherapy.

[16]  O. O. Okusanya,et al.  Impact of Spore Biology on the Rate of Kill and Suppression of Resistance in Bacillus anthracis , 2009, Antimicrobial Agents and Chemotherapy.

[17]  R. Simpson.  The destruction of bacterial spores , 1983 .

[18]  H. Levy,et al.  Antibiotics Cure Anthrax in Animal Models , 2011, Antimicrobial Agents and Chemotherapy.

[19]  E. D. Barnhart.  Physicians Desk Reference , 1990 .

[20]  T. Koehler,et al.  Inactivation of Bacillus anthracis spores in murine primary macrophages , 2006, Cellular microbiology.

[21]  S. Pillai,et al.  Antistaphylococcal agents. , 2009, Infectious disease clinics of North America.

[22]  B. Ivins,et al.  Evidence for plasmid-mediated toxin production in Bacillus anthracis , 1983, Infection and immunity.

[23]  D. Stevens,et al.  Impact of antibiotics on expression of virulence-associated exotoxin genes in methicillin-sensitive and methicillin-resistant Staphylococcus aureus. , 2007, The Journal of infectious diseases.

[24]  E. Wang,et al.  Murine Model of Pulmonary Anthrax: Kinetics of Dissemination, Histopathology, and Mouse Strain Susceptibility , 2004, Infection and Immunity.

[25]  J. Ezzell,et al.  Postexposure prophylaxis against experimental inhalation anthrax. , 1993, The Journal of infectious diseases.

[26]  A. Moir,et al.  How do spores germinate? , 2006, Journal of applied microbiology.

[27]  J. Larabee,et al.  Effects of Endogenous d-Alanine Synthesis and Autoinhibition of Bacillus anthracis Germination on In Vitro and In Vivo Infections , 2007, Infection and Immunity.

[28]  K. Bush,et al.  Pharmacokinetic Considerations and Efficacy of Levofloxacin in an Inhalational Anthrax (Postexposure) Rhesus Monkey Model , 2006, Antimicrobial Agents and Chemotherapy.

[29]  Elizabeth R. Zell,et al.  Antimicrobial Postexposure Prophylaxis for Anthrax: Adverse Events and Adherence , 2002, Emerging infectious diseases.

[30]  I. Brook,et al.  In vitro resistance of Bacillus anthracis Sterne to doxycycline, macrolides and quinolones. , 2001, International journal of antimicrobial agents.

[31]  W. Craig,et al.  Activities of Clindamycin, Daptomycin, Doxycycline, Linezolid, Trimethoprim-Sulfamethoxazole, and Vancomycin against Community-Associated Methicillin-Resistant Staphylococcus aureus with Inducible Clindamycin Resistance in Murine Thigh Infection and In Vitro Pharmacodynamic Models , 2008, Antimicrobial Agents and Chemotherapy.

[32]  A. Athamna,et al.  Selection of Bacillus anthracis isolates resistant to antibiotics. , 2004, The Journal of antimicrobial chemotherapy.

[33]  Brian Van Scoy,et al.  The Combination of Meropenem and Levofloxacin Is Synergistic with Respect to both Pseudomonas aeruginosa Kill Rate and Resistance Suppression , 2010, Antimicrobial Agents and Chemotherapy.

[34]  H. Aoki,et al.  The Oxazolidinone Linezolid Inhibits Initiation of Protein Synthesis in Bacteria , 1998, Antimicrobial Agents and Chemotherapy.

[35]  G. Drusano,et al.  Is 60 Days of Ciprofloxacin Administration Necessary for Postexposure Prophylaxis for Bacillus anthracis? , 2008, Antimicrobial Agents and Chemotherapy.

[36]  G. Rahav,et al.  Type II topoisomerase mutations in Bacillus anthracis associated with high-level fluoroquinolone resistance. , 2004, The Journal of antimicrobial chemotherapy.

[37]  D. Stevens,et al.  Antibiotic effects on bacterial viability, toxin production, and host response. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.